Mutations in centrosome genes deplete neural progenitor cells (NPCs) during brain development, causing microcephaly. While NPC attrition is linked to TP53-mediated cell death in several microcephaly models, how TP53 is activated remains unclear. In cultured cells, mitotic delays resulting from centrosome loss prevent the growth of unfit daughter cells by activating a pathway involving 53BP1, USP28, and TP53, termed the mitotic surveillance pathway. Whether this pathway is active in the developing brain is unknown. Here, we show that the depletion of centrosome proteins in NPCs prolongs mitosis and increases TP53-mediated apoptosis. Cell death after a delayed mitosis was rescued by inactivation of the mitotic surveillance pathway. Moreover, 53BP1 or USP28 deletion restored NPC proliferation and brain size without correcting the upstream centrosome defects or extended mitosis. By contrast, microcephaly caused by the loss of the non-centrosomal protein SMC5 is also TP53-dependent but is not rescued by loss of 53BP1 or USP28. Thus, we propose that mutations in centrosome genes cause microcephaly by delaying mitosis and pathologically activating the mitotic surveillance pathway in the developing brain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780150PMC
http://dx.doi.org/10.15252/embj.2020106118DOI Listing

Publication Analysis

Top Keywords

mitotic surveillance
16
surveillance pathway
16
53bp1 usp28
12
centrosome defects
8
mutations centrosome
8
centrosome genes
8
cell death
8
developing brain
8
centrosome
6
pathway
6

Similar Publications

Aim: To investigate additional factors contributing to the pathophysiology of chemotherapy-induced oral mucositis and periodontitis beyond the systemic immune suppression caused by the chemotherapeutic agent 5-Fluorouracil (5-FU).

Methods: 5-Fluorouracil was topically delivered to the non-keratinized, rapidly proliferating junctional epithelium (JE) surrounding the dentition, and acts as an immunologic and functional barrier to bacterial ingression. Various techniques, including EdU incorporation, quantitative immunohistochemistry (qIHC), histology, enzymatic activity assays, and micro-computed tomographic (μCT) imaging, were employed to analyze the JE at multiple time points following topical 5-FU treatment.

View Article and Find Full Text PDF

Canine oral melanoma (OM) exhibits poor prognosis and limited treatment options. The success of immune checkpoint inhibitors (ICIs) in human melanoma has driven interest in similar therapeutic approaches in the dog, although the immunosuppressive mechanisms adopted by canine OM remain unclear. This study aimed to evaluate the expression of the immune checkpoints PD-1/PD-L1 and CTLA-4 by RNAscope in situ hybridization (ISH) in canine OM, to investigate their expression pattern and explore their potential role in melanoma progression.

View Article and Find Full Text PDF

Errors during cell division lead to aneuploidy, which is associated with genomic instability and cell transformation. In response to aneuploidy, cells activate the tumour suppressor p53 to elicit a surveillance mechanism that halts proliferation and promotes senescence. The molecular sensors that trigger this checkpoint are unclear.

View Article and Find Full Text PDF

Malignant Melanoma: Vitamin D Status as a Risk and Prognostic Factor - Meta-analyses and Systematic Review.

Anticancer Res

January 2025

Department of Dermatology, Venereology, Allergology, Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University Medical Center, Homburg, Germany.

Background/aim: Solar ultraviolet radiation represents the most important environmental risk factor for skin cancer. However, vitamin D synthesis from sun exposure has been reported to exert anti-carcinogenic effects on melanocytes in vitro. This justifies the ongoing debate whether vitamin D status can be considered a risk and prognostic for primary cutaneous malignant melanoma.

View Article and Find Full Text PDF

Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma.

Breast Cancer Res Treat

December 2024

Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland.

Article Synopsis
  • The study aims to improve predictions of disease outcomes for breast cancer patients undergoing neoadjuvant treatment (NAT) by analyzing clinical and histopathological data.
  • Researchers evaluated a cohort of 257 Finnish breast cancer patients over 13 years, identifying significant prognostic factors and previously overlooked histological features that correlate with treatment response and survival.
  • The findings suggest the importance of re-assessing biomarkers post-treatment and developing personalized surveillance and treatment strategies based on comprehensive evaluations of patient data and risk factors.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!